Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 4/20 | 0.35 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 7/20 | 0.32 |
| ▸ | HTR2A | P28223 | 6/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 5/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29088975 | 0.70 | MAPK14 (0.33) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2487946 | 0.67 | SLC5A2 (0.36) | HTR2CHTR2AHTR2B | |
| SCHEMBL30228097 | 0.66 | KDM1A (0.35) | HTR2CHTR2AKDM1AKDM1BHTR2B | |
| SCHEMBL12553033 | 0.66 | HTR2C (0.37) | HTR2CHTR2AKDM1AKDM1BSLC6A2 | |
| SCHEMBL1875659 | 0.66 | KDM1A (0.35) | HTR2CHTR2AKDM1AKDM1BHTR2B | |
| SCHEMBL5040961 | 0.66 | HTR2C (0.47) | HTR2CHTR2AKDM1AKDM1BHTR2B | |
| SCHEMBL3336712 | 0.63 | SLC6A4 (0.50) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 | |
| SCHEMBL12656462 | 0.63 | KDM1A (0.34) | HTR2CHTR2AKDM1AKDM1BHTR2B | |
| SCHEMBL31725635 | 0.63 | KDM1A (0.34) | HTR2CHTR2AKDM1AKDM1BHTR2B | |
| SCHEMBL21505478 | 0.63 | CYP11B1 (0.45) | HTR2CHTR2AKDM1AKDM1BHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425542-A1 | CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS | NUCORION PHARMACEUTICALS INC (US) | 2024-12-26 | — | — | US | disclosed |
| US-12110311-B2 | Cyclic deoxyribonucleotide compounds | NUCORION PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20220298199-A1 | CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS | NUCORION PHARMACEUTICALS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-11427550-B2 | 5-fluorouracil compounds | NUCORION PHARMACEUTICALS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3999519-A1 | CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS | NUCORION PHARMACEUTICALS, INC. (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298199-A1 | CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS | DPYD, TYMP, TYMS | HTR1A 3685/4885IDO1 3984/4885AGXT 1327/4885 |
| US-20240425542-A1 | CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS | DPYD, TYMP, TYMS | HTR1A 3685/4885IDO1 3984/4885AGXT 1327/4885 |
| US-12110311-B2 | Cyclic deoxyribonucleotide compounds | DPYD, TYMP, TYMS | HTR1A 3685/4885IDO1 3984/4885AGXT 1327/4885 |
| US-11427550-B2 | 5-fluorouracil compounds | DPYD, DHFR, MTHFD1 | HTR1A 328/4885IDO1 3948/4885AGXT 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.